Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis

  • Santamaría, Eva
  • Rodriguez-Ortigosa, Carlos
  • Uriarte, Iker
  • Latasa, Maria Ujue
  • Urtasun Alonso, Raquel
  • Álvarez-Sola, Gloria
  • Bárcena-Varela, Marina
  • Colyn, Leticia
  • Arcelus, Sara
  • Jiménez, Maddalen
  • Deutschmann, Kathleen
  • Peleteiro Vigil, Ana
  • Gómez Cambronero, Julián
  • Milkiewicz, Malgorzata
  • Milkiewicz, Piotr
  • Sangro, Bruno
  • Keitel, Verena
  • Monte, María J.
  • Marin, Jose J. G.
  • Fernández-Barrena, Maite G.
  • Ávila, Matías A.
  • Berasain, Carmen
Intrahepatic accumulation of bile acids (BAs) causes hepatocellular injury. Upon liver damage, a potent protective response is mounted to restore the organ’s function. Epidermal growth factor receptor (EGFR) signaling is essential for regeneration after most types of liver damage, including cholestatic injury. However, EGFR can be activated by a family of growth factors induced during liver injury and regeneration. We evaluated the role of the EGFR ligand, amphiregulin (AREG), during cholestatic liver injury and regulation of AREG expression by BAs. First, we demonstrated increased AREG levels in livers from patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). In two murine models of cholestatic liver injury, bile duct ligation (BDL) and alpha‐naphthyl‐isothiocyanate (ANIT) gavage, hepatic AREG expression was markedly up‐regulated. Importantly, Areg–/– mice showed aggravated liver injury after BDL and ANIT administration compared to Areg+/+ mice. Recombinant AREG protected from ANIT and BDL‐induced liver injury and reduced BA‐triggered apoptosis in liver cells. Oral BA administration induced ileal and hepatic Areg expression, and, interestingly, cholestyramine feeding reduced postprandial Areg up‐regulation in both tissues. Most interestingly, Areg–/– mice displayed high hepatic cholesterol 7 α‐hydroxylase (CYP7A1) expression, reduced serum cholesterol, and high BA levels. Postprandial repression of Cyp7a1 was impaired in Areg–/– mice, and recombinant AREG down‐regulated Cyp7a1 mRNA in hepatocytes. On the other hand, BAs promoted AREG gene expression and protein shedding in hepatocytes. This effect was mediated through the farnesoid X receptor (FXR), as demonstrated in Fxr–/– mice, and involved EGFR transactivation. Finally, we show that hepatic EGFR expression is indirectly induced by BA‐FXR through activation of suppressor of cytokine signaling‐3 (SOC3). Conclusion: AREG‐EGFR signaling protects from cholestatic injury and participates in the physiological regulation of BA synthesis., Grants SAF 2016-75972R from Ministerio de Economía y Competitividad, Spain. Grants FIS PI16/01126 and PI16/00598 from Instituto de Salud Carlos III (ISCIII).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma

  • Bárcena-Varela, Marina
  • Caruso, Stefano
  • Llerena, Susana
  • Álvarez-Sola, Gloria
  • Uriarte, Iker
  • Latasa, Maria Ujue
  • Urtasun Alonso, Raquel
  • Rebouissou, Sandra
  • Álvarez Fraga, Laura
  • Jiménez, Maddalen
  • Santamaría, Eva
  • Rodriguez-Ortigosa, Carlos
  • Mazza, Giuseppe
  • Rombouts, Krista
  • San José Eneriz, Edurne
  • Rabal, Obdulia
  • Agirre, Xabier
  • Iraburu, María
  • Santos-Laso, Álvaro
  • Bañales, Jesús María
  • Zucman-Rossi, Jessica
  • Prósper, Felipe
  • Oyarzabal, Julen
  • Berasain, Carmen
  • Ávila, Matías A.
  • Fernández-Barrena, Maite G.
Epigenetic modifications such as DNA and histone methylation functionally cooperate in fostering tumor growth, including that of hepatocellular carcinoma (HCC). Pharmacological targeting of these mechanisms may open new therapeutic avenues. We aimed to determine the therapeutic efficacy and potential mechanism of action of our dual G9a histone‐methyltransferase and DNA‐methyltransferase 1 (DNMT1) inhibitor in human HCC cells and their crosstalk with fibrogenic cells. The expression of G9a and DNMT1, along with that of their molecular adaptor ubiquitin‐like with PHD and RING finger domains‐1 (UHRF1), was measured in human HCCs (n = 268), peritumoral tissues (n = 154), and HCC cell lines (n = 32). We evaluated the effect of individual and combined inhibition of G9a and DNMT1 on HCC cell growth by pharmacological and genetic approaches. The activity of our lead compound, CM‐272, was examined in HCC cells under normoxia and hypoxia, human hepatic stellate cells and LX2 cells, and xenograft tumors formed by HCC or combined HCC+LX2 cells. We found a significant and correlative overexpression of G9a, DNMT1, and UHRF1 in HCCs in association with poor prognosis. Independent G9a and DNMT1 pharmacological targeting synergistically inhibited HCC cell growth. CM‐272 potently reduced HCC and LX2 cells proliferation and quelled tumor growth, particularly in HCC+LX2 xenografts. Mechanistically, CM‐272 inhibited the metabolic adaptation of HCC cells to hypoxia and induced a differentiated phenotype in HCC and fibrogenic cells. The expression of the metabolic tumor suppressor gene fructose‐1,6‐bisphosphatase (FBP1), epigenetically repressed in HCC, was restored by CM‐272. Conclusion: Combined targeting of G9a/DNMT1 with compounds such as CM‐272 is a promising strategy for HCC treatment. Our findings also underscore the potential of differentiation therapy in HCC., Grants SAF2016-75972R, SAF2014-54191R and SAF2017-88933R from Ministerio de Economía, Spain. Grant FISPI16/01126, PI15/01132, and Miguel Servet Programme CON14/00129 to JMB, from Instituto de Salud Carlos III (ISCIII).